{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:17:49Z","timestamp":1778811469357,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.nefroe.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:35:21Z","timestamp":1749713721000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fabry disease as a trigger of immune-mediated glomerular disease: Clinical hypotheses and literature review"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-7129","authenticated-orcid":false,"given":"Javier","family":"Mart\u00ednez de Victoria Carazo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haylen","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-2682","authenticated-orcid":false,"given":"Francisco Javier","family":"De la Hera Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-0207","authenticated-orcid":false,"given":"Carlos","family":"Ma\u00f1ero Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-707X","authenticated-orcid":false,"given":"C\u00e9sar","family":"Ram\u00edrez Tortosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Callejas Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.04.010_bib0125","first-page":"e37048","article-title":"Fabry disease and its management: a literature analysis","volume":"15","author":"Besekar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0135","doi-asserted-by":"crossref","first-page":"103030","DOI":"10.1016\/j.autrev.2021.103030","article-title":"Pathogenesis-based new perspectives of management of ANCA-associated vasculitis","volume":"21","author":"Sciascia","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0140","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1136\/annrheumdis-2019-215476","article-title":"What rheumatologist should know about Fabry disease","volume":"79","author":"Moiseev","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000916","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis","volume":"35","author":"Yazici","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0150","first-page":"73","article-title":"Coexistence of Fabry's disease and necrotizing and crescentic glomerulonephritis","volume":"55","author":"Singh","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000063287","article-title":"Crescentic glomerulonephritis in a patient with heterozygous Fabry's disease","volume":"92","author":"Shimazu","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1471-2369-15-157","article-title":"A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link","volume":"15","author":"Hanaoka","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40620-022-01533-4","article-title":"ANCA-negative pauci-immune crescentic glomerulonephritis associated with Fabry disease: lesson for the clinical nephrologist","volume":"36","author":"Ronsin","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/978-1-4939-9424-3_31","article-title":"Neutrophil extracellular traps","volume":"1982","author":"Rada","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0161-5890(78)90130-X","article-title":"Characterization of antibodies against ceramide trihexoside and globoside","volume":"15","author":"Hamers","year":"1978","journal-title":"Immunochemistry"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10545-007-0513-2","article-title":"High incidence of autoantibodies in Fabry disease patients","volume":"30","author":"Martinez","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0185","doi-asserted-by":"crossref","first-page":"1420067","DOI":"10.3389\/fcvm.2024.1420067","article-title":"Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications","volume":"11","author":"Kurdi","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0190","doi-asserted-by":"crossref","first-page":"1307558","DOI":"10.3389\/fimmu.2024.1307558","article-title":"Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy","volume":"15","author":"Laffer","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000183006","article-title":"Kidney involvement in systemic lupus erythematosus and Fabry's disease","volume":"34","author":"Rosenmann","year":"1983","journal-title":"Nephron"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0205","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3904\/kjim.2015.30.6.925","article-title":"Fabry disease previously diagnosed as Henoch\u2013Schonlein purpura","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0210","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/BF00714291","article-title":"Polyarteritis nodosa-like necrotizing vasculitis in Fabry disease","volume":"16","author":"Drachenberg","year":"1993","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archdermatol.2007.20","article-title":"Cutaneous polyarteritis nodosa in a patient with fabry disease","volume":"144","author":"Chen","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00296-019-04453-y","article-title":"Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review","volume":"40","author":"Arbel\u00e1ez-Cort\u00e9s","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1297\/cpe.20.95","article-title":"Fabry disease superimposed on overt autoimmune hypothyroidism","volume":"20","author":"Katsumata","year":"2011","journal-title":"Clin Pediatric Endocrinol"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12969-021-00563-9","article-title":"Frequency of Fabry disease in a juvenile idiopathic arthritis cohort","volume":"19","author":"Paim-Marques","year":"2021","journal-title":"Pediatric Rheumatol Online J"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0235","first-page":"28","article-title":"Enfermedad de Fabry asociada a artritis reumatoide. Una encrucijada multisist\u00e9mica","volume":"20","author":"Arias Mart\u00ednez","year":"2003","journal-title":"Anales Med Intern (Madrid, Spain: 1984)"},{"key":"10.1016\/j.nefroe.2025.04.010_bib0240","first-page":"100650","article-title":"Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy","volume":"25","author":"Tsukimura","year":"2020","journal-title":"Mol Genet Metab Rep"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:35:25Z","timestamp":1749713725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2013251425000641"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.04.010","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease as a trigger of immune-mediated glomerular disease: Clinical hypotheses and literature review","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}